Twenty-two out of these 50 ESBL-producing Salmonella isolates showed variable levels of resistance to the aminoglycosides tested (gentamicin, kanamycin and streptomycin) and were screened for detection of the armA methylase gene by PCR, as described by Gonzalez-Zorn et al. 7 The armA gene was detected in the isolates showing high-level resistance (no inhibition zone) to all of the aminoglycosides tested: Salmonella Typhimurium (n¼13); and Salmonella 4,12:-:1,2 (n¼1). The armA gene was also detected in four isolates of Salmonella Enteritidis displaying high-level resistance to gentamicin and kanamycin but susceptibility to streptomycin. No armA gene was detected among the four isolates displaying high-level resistance to gentamicin and streptomycin but susceptibility to kanamycin. Sequencing of the bla CTX-M genes from the 18 armA-positive isolates allowed identification of the CTX-M-15 determinant. Moreover, 13 of them co-produced CMY-2 ( Table 1) .
PFGE analysis of 12 armA-positive isolates of Salmonella Typhimurium revealed an identical pattern, suggesting the spread of an epidemic clone. The four armA-positive Salmonella Enteritidis isolates displayed three distinct PFGE patterns, most likely indicating horizontal spread of the resistance determinants (Table 1) .
So far, enterobacterial isolates co-harbouring the bla CTX-M-15 and armA genes have been identified as Klebsiella pneumoniae, Klebsiella oxytoca and E. coli. 5, 9, 10 Interestingly, in the study by Bogaerts et al., 5 the patients seemed to have been transferred from Algeria. We report here the concomitant occurrence of these two genes among ESBL-producing S. enterica isolates that have been recovered in Algeria. In that country, the armA gene had been previously identified among CTX-M-3-producing S. enterica serotype Senftenberg isolates. 4 The emergence of the armA methylase gene among CTX-M-15 ESBL-harbouring strains of S. enterica is a public health concern in Algeria. It certainly requires the implementation of a strict hospital infection control policy as well as the promotion of epidemiological surveys in the community in order to avoid the dissemination of such multiresistant strains.
Sir, In the last decade, Actinobaculum schaalii, a Gram-positive, facultative anaerobic, coccoid rod, 1 has emerged as a uropathogen, mainly in elderly patients with underlying urological predispositions. 2 -4 Due to difficulties in cultivating A. schaalii, the incidence of the bacteria has probably been underestimated for many years.
Unless microscopy of Gram's stains or wet smear is used for screeing urinary samples, specimens will often not be cultured in an atmosphere supporting growth of A. schaalii. However, even when cultured in a CO 2 -enriched atmosphere A. schaalii can often only be identified by PCR, as a study has shown that in 90% of the cases it occurs together with fast-growing commonly known uropathogens, and thus is overlooked. 3 A. schaalii is susceptible in vivo to nearly all b-lactams, such as amoxicillin or cephalosporins, but is resistant to trimethoprim and ciprofloxacin. 4 In a recent study of A. schaalii performed by Cattoir et al., 5 the MICs of 12 different antimicrobial agents, including those commonly used for the treatment of urinary tract infections (UTIs), were determined. Pivmecillinam was not included, but it is often the antibiotic of choice for the oral treatment of UTIs in Scandinavia, e.g. in Denmark it accounts for approximately half of the defined daily doses used for UTIs. 6, 7 We therefore selected 18 clinical A. schaalii isolates and measured the MICs of mecillinam.
Fourteen of the isolates were obtained from urine specimens and four were from blood cultures. As a confirmatory test, all isolates were screened using a real-time PCR assay specific for A. schaalii, 3 and the A. schaalii strain CCUG 27420 was used as a reference. The susceptibility testing was performed on Schaedler agar (Oxoid) supplemented with 5 mg/mL haemin, 1 mg/mL vitamin K1 and 5% sheep blood. An inoculum suspension adjusted to a turbidity equivalent to that of a 1 McFarland standard in 0.9% NaCl was spread on to the agar and incubated under anaerobic conditions at 358C for 48 h. The MIC of mecillinam was determined for all isolates using Etest (AB bioMérieux, Solna, Sweden). Bacteroides fragilis ATCC 25285 was used as a quality control strain.
The susceptibility testing of mecillinam against the 18 A. schaalii isolates showed MIC values in the range 0.5-2.0 mg/L (Table 1) , and the MIC 50 and MIC 90 were 1.0 and 2.0 mg/L, respectively. This is consistent with previous findings in which nine strains of A. schaalii were susceptible to mecillinam (amdinocillin), with an MIC range of 0.25-1.5 mg/L, an MIC 50 of 0.5 mg/L and an MIC 90 of 1.0 mg/L. 2 The present study suggests that pivmecillinam will be effective as an alternative to other b-lactams in the treatment of A. schaalii UTIs, although this b-lactam is not usually used against Gram-positive bacteria. 6 The advantages of choosing pivmecillinam include the low level of resistance in urinary pathogens, in addition to the possibility of achieving very high urinary concentrations (.200 mg/L) due to active excretion into the urine. 6 In conclusion, pivmecillinam as a first-choice antibiotic against UTIs probably covers A. schaalii, both when A. schaalii is identified in monocultures and more frequently when it occurs as a co-pathogen with common fast-growing uropathogens.
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